期刊文献+

Onconase研究与开发的最新进展 被引量:6

Latest Advances in the Research and Development of Onconase
原文传递
导出
摘要 Onconase是一种在北方豹蛙(Rana pipiens)卵母细胞和早期胚胎内存在的核糖核酸酶,是RNase A超家族中的一员,研究证实它在体内外对多种肿瘤均具显著杀伤作用。Onconase目前已经作为抗肿瘤药物上市,用于治疗恶性间皮瘤。Onconase结构独特,高度稳定。在临床上,Onconase具有副反应较轻,免疫原性低和不易产生耐药性等优点。因此Onconase的研究在学术上和医学应用上均具重要意义。本文综述了Onconase的结构特点、催化专一性、细胞毒性、体内外抗肿瘤活性及其临床应用的最新进展,并讨论了与其相关的一些重要问题。 Onconase,a member of RNase A superfamily,is a ribonuclease originally purified from oocytes and early embryo of Nothern leopard frog(Rana pipiens),which shows striking anti- tumor potential in vitro and in vivo.Onconase has been approved as an orphan drug applied for the treatment of malignant mesothelioma.Onconase has a unique structure and high stability.In clin- ics,it has shown mild side-effects,low immunogenicity and infrequent drug-resistance.Therefore,the research on Onconase possesses both important theoretical and clinically applied value.This paper reviews the latest advances of the studies on its structural characteristics,catalytic specificity, cytotoxicity,antitumor activity and clinical application.Meanwhile some important problems related to Onconase are discussed.
出处 《中国细胞生物学学报》 CAS CSCD 2010年第6期927-934,共8页 Chinese Journal of Cell Biology
关键词 ONCONASE RNASE 抗肿瘤 免疫毒素 Onconase RNase antitumor immunotoxin
  • 相关文献

参考文献48

  • 1Ledoux L. Action of ribonuclease on two solid tumours in vivo. Nature 1955; 176: 36-7.
  • 2Ardelt W, Ardelt BD. Ribonucleases as potential rnodalities in anticancer therapy. Eur J Pharmacol 2009; 625: 181-9.
  • 3Yun TK, Kim YK, Kim BS, Park HK, Park SS, Koh CS, et al. Clinical studies on the cancinolytic action of bovine pancre- atic ribonuclease. J Korean Cancer Res Assoc 1972; 7: 23-481.
  • 4Darzynkiewicz Z ,Carter SP ,Mikulski SM, Ardelt WJ, Shogen K. Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent. Cell Tissue Kinet 1988; 21(3): 169-82.
  • 5Ardelt W, Mikulski SM, Shogen K. Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. Homology to pancreatic ribonucleases. J Biol Chem 1991; 266(1): 245-51.
  • 6Kreitman RJ. Recombinant immunotoxins containing trun- cated bacterial toxins for the treatment of hematologic malignancies. Bin Drugs 2009; 23:1-13.
  • 7Wu Y, Mikulski SM, Ardelt W,Rybak SM, Youle RJ. A cyto- toxic ribonuclease. Study of the mechanism of onconase cytotoxicity. J Biol Chem 1993; 268(14): 10686-93.
  • 8Newton DL, Hansen HI, Mikulski SM, Goldenberg DM, Rybak SM. Potent and specific antitumor effects of an anti-CD22- targeted eytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood 2001; 97(2): 528-35.
  • 9Saxena SK, Sirdeshmukh R, Ardelt W, Mikulski SM, Shogen K, Youle RJ. Entry into cells and selective degradation of tRNAs by a cytotoxic member of the RNase A family. J Biol Chem 2002; 277 (17): 15142-6.
  • 10Iordanov MS, Ryabinina OP, Wong J, Dinh TH, Newton DL, Rybak SM, et al. Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cyto- toxic mechanisms different from inhibition of protein synthesis. Cancer Res 2000; 60(7):1983-94.

同被引文献44

引证文献6

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部